<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303978</url>
  </required_header>
  <id_info>
    <org_study_id>DN10007</org_study_id>
    <nct_id>NCT01303978</nct_id>
  </id_info>
  <brief_title>Phase II Proof-of-concept Study of APD421</brief_title>
  <official_title>Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>24 hours after cisplatin dosing</time_frame>
    <description>No emesis or use of rescue medication</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>APD421 starting dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421</intervention_name>
    <description>Single dose</description>
    <arm_group_label>APD421 starting dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥ 18 years of age&#xD;
&#xD;
          2. Ability and willingness to give written informed consent&#xD;
&#xD;
          3. Patients scheduled to receive, on day 1 of their chemotherapy, a first cisplatin&#xD;
             chemotherapy infusion at a dose of 50 mg/m2 or greater&#xD;
&#xD;
          4. Karnofsky performance score ≥ 60%&#xD;
&#xD;
          5. Adequate cardiac, hepatic and renal function&#xD;
&#xD;
               -  QTc interval &lt; 500 ms&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &lt; 5 x&#xD;
                  upper limit normal (ULN)&#xD;
&#xD;
               -  Bilirubin &lt; 3 x ULN&#xD;
&#xD;
               -  Creatinine &lt; 2 x ULN&#xD;
&#xD;
          6. Adequate haematological function&#xD;
&#xD;
               -  Haemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  White blood count ≥ 3.0 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
          7. For females of child-bearing potential: ability and willingness to use a highly&#xD;
             effective form of contraception (e.g., abstinence from sexual intercourse, surgical&#xD;
             sterilisation (of subject or partner) or a double-barrier method of contraception such&#xD;
             as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in&#xD;
             conjunction with partner's use of a condom) during the study and for a period of at&#xD;
             least 48 hours afterwards.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients scheduled to receive, prior to or in the 24 hours after cisplatin, any&#xD;
             chemotherapeutic agent with a high or moderate emetic risk, see Appendix 4.&#xD;
&#xD;
          2. Patients scheduled to receive paclitaxel or docetaxel&#xD;
&#xD;
          3. Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening&#xD;
             or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours&#xD;
             after cisplatin administration&#xD;
&#xD;
          4. Patients receiving APD421 for any indication within the last 2 weeks&#xD;
&#xD;
          5. Patients who are allergic to APD421 or any of the excipients of APD421&#xD;
&#xD;
          6. Patients with a pre-existing vestibular disorder&#xD;
&#xD;
          7. Patients being treated with regular anti-emetic therapy including corticosteroids&#xD;
&#xD;
          8. Patients receiving inhaled corticosteroids, unless started more than one month prior&#xD;
             to the expected date of study entry&#xD;
&#xD;
          9. Patients being treated with medications which could induce torsades de pointes,&#xD;
             including Class Ia antiarrhythmic agents such as quinidine, disopyramide,&#xD;
             procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and&#xD;
             other medications such as bepridil, cisapride, thioridazine, methadone, IV&#xD;
             erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin&#xD;
&#xD;
         10. Patients being treated with xxx&#xD;
&#xD;
         11. Patients receiving benzodiazepines, unless on a stable dose for at least one month&#xD;
             prior to the expected date of study entry&#xD;
&#xD;
         12. Patients with pre-existing nausea or vomiting in the 24 hours before receiving&#xD;
             cisplatin chemotherapy, e.g. anticipatory emesis&#xD;
&#xD;
         13. Patients who are pregnant or breast feeding&#xD;
&#xD;
         14. Patients with a history of alcohol abuse&#xD;
&#xD;
         15. Patients with pre-existing, clinically significant cardiac arrhythmia&#xD;
&#xD;
         16. Any other concurrent disease or illness that, in the opinion of the investigator makes&#xD;
             the patient unsuitable for the study&#xD;
&#xD;
         17. Patients who have participated in another study within the previous 28 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester NHS Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

